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Introduction
Pseudomonas aeruginosa is an opportunistic patho-
gen with increasing role in nosocomial outbreaks. It 
produces multiple virulence factors that have been 
implicated in both-pathogenesis and bacterial quorum 
sensing. P. aeruginosa strains virulence factors may be 
linked to bacterial cell surface or released outside the 
cells. Exoenzyme S is a secreted protein toxin with 
ADP-ribosyltransferase and GTP-ase activity (Barbieri 
and Sun, 2004). This toxin is encoded by exoS gene 
located at 4303141–4304502 chromosome position of 
P. aeruginosa PAO1 strain (Stover et al., 2000). Exo-
enzyme S is formed by 453 amino acids and released 
in type-III secretion system directly to the cytosol of 
the animal epithelial cells (Barbieri, 2000; Krueger and 
Barbieri, 1995; Rumbaugh et al., 1999b). Its main bio-
logical activity is the protein synthesis inhibition in 
eukaryotic cells. Exoenzyme S inhibits also phago-
cytosis of bacterial cells by macrophages. In this man-
ner, it can interfere in host immunological response 
(Barbieri, 2000; Frithz-Lindsten et al., 1997). It is also 
able to induce apoptosis of lymphocyte-T cells by their 
DNA fragmentation (Bruno et al., 2000).
There are no direct criteria for P. aeruginosa strains 
classification into multidrug-resistant (MDR) group in 
the relevant literature (Falagas et al., 2006; Magiorakos 
et al., 2012). Many different authors usually provide 
their own definitions established for their studies pur-
poses. According to the definitions formed in 1994 by 
the American Cystic Fibrosis Foundation, MDR strains 
should express resistance to all drugs from at least two 
different therapeutic groups, e.g. beta-lactams, amino-
glycosides and quinolones. Such criterion was used by 
Hill et al. (2005). A different definition had been used 
by Tam et al. (2005). According to them, strains should 
be classified as MDR while resistance to ceftazidime, 
imipenem, tobramycin and ciprofloxacin can be found. 
Similar criteria were used by Obritsch et al. (2004) in 
the analysis of antimicrobial sensitivity of P. aeruginosa 
strains derived from the patients of the intensive care 
units, isolated in the United States between 1993 and 
2002. Hsu et al. (2005) used both criteria – established 
by American Cystic Fibrosis Foundation, and their 
own. These authors had chosen a few indicators of 
antimicrobial resistance: piperacillin/tazobactam, cef-
tazidime and cefepime, imipenem, gentamicin, amika-
cin/tobramycin and ciprofloxacin/levofloxacin. Strains 
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A b s t r a c t
Pseudomonas aeruginosa rods are one of the most commonly isolated microorganisms from clinical specimens, usually responsible for 
nosocomial infections. Antibiotic-resistant P. aeruginosa strains may present reduced expression of virulence factors. This fact may be 
caused by appropriate genome management to adapt to changing conditions of the hospital environment. Virulence factors genes may 
be replaced by those crucial to survive, like antimicrobial resistance genes. The aim of this study was to evaluate, using PCR, the occurrence 
of exoenzyme S-coding gene (exoS) in two distinct groups of P. aeruginosa strains: 83 multidrug-sensitive (MDS) and 65 multidrug-resistant 
(MDR) isolates. ExoS gene was noted in 72 (48.7%) of the examined strains: 44 (53.0%) MDS and 28 (43.1%) MDR. The observed differ-
ences were not statistically significant (p = 0.1505). P. aeruginosa strains virulence is rather determined by the expression regulation of the 
possessed genes than the difference in genes frequency amongst strains with different antimicrobial susceptibility patterns.
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classified as MDR were resistant to at least two out of 
the antimicrobial groups mentioned above.
The aim of this study was to determine the exoS 
gene frequency and its difference in multidrug-sensitive 
(MDS) and MDR P. aeruginosa strains groups.
Experimental
Materials and Methods
A total of 148 non-duplicated P. aeruginosa clinical 
strains (83 MDS and 65 MDR) collected in the Depart-
ment of Microbiology of dr. A. Jurasz University Hos-
pital No 1 in Bydgoszcz were included in the study. The 
strains identification was done on the basis of standard 
microbiological procedures.
For antimicrobial susceptibility tests, using disc-dif-
fusion method on Mueller-Hinton Agar (Becton Dickin-
son), the following antimicrobials were used: ticarcillin, 
piperacillin, ticarcillin/clavulanate, piperacillin/tazo-
bactam, ceftazidime, cefepime, aztreonam, imipenem, 
meropenem, gentamicin, tobramycin, amikacin, netil-
micin, ciprofloxacin (Becton Dickinson). Results of 
the antimicrobial susceptibility tests were interpreted 
according to EUCAST Recommendations. P. aeruginosa 
ATCC 27853 and Escherichia coli ATCC 25922 strains 
served as susceptibility testing quality controls. All the 
strains included into the study were, respectively, sensi-
tive or resistant to all antimicrobials out of three groups: 
beta-lactams, aminoglycosides and fluoroquinolones 
and classified as MDS or MDR.
Bacterial genomic DNA was isolated with Genomic 
Mini kit (A&A Biotechnology), according to the manu-
facturer’s protocol. In order to confirm the DNA isola-
tion correctness and to avoid false-negative results all 
DNA samples were checked firstly: all of them were 
mixed separately with Loading Buffer DNA IV (Appli-
Chem) and separated in 1% agarose gel (Bio-Rad) in 
1 × TBE (Tris-Borate/EDTA, Bio-Rad) at 9 V/cm dur-
ing one hour using MINI SUB™ DNA CELL (Bio-Rad) 
apparatus. After staining for 30 minutes in ethidium 
bromide solution and subsequent washing step for 
20 minutes with deionized water, gels were visualized 
in UV light with Quantity One (Bio-Rad) program. 
DNA samples were then stored at 4°C until further use.
The prevalence of the exoenzyme S-encoding gene 
was determined by PCR. The amplification procedure 
was carried out according to Lanotte et al. (2004), in 
0.2 ml test tubes (Eppendorf) in the final volume of 
20 μl. Taq polymerase was used with the total activity 
of 1 U per sample in 1 × BD buffer, MgCl2 at the final 
concentration of 1.5 mM (FirePol DNA Polymerase, 
Solis BioDyne) and dNTPs set at the final concentra-
tion of 200 μM (Solis BioDyne) were applied. Following 
primers were used: exoS F and exoS R, with sequences 
5’→3’: -CTTGAAGGGACTCGACAAGG- and -TTCA 
GGTCCGCGTAGTGAAT- (Integrated DNA Techno lo-
gies), respectively, both at the final amount of 12.5 pmol 
per reaction. Isolated DNA samples were added sub-
sequently. DNA isolated from P. aeruginosa PAO1 
strain served as an amplification positive control. In 
the amplification procedure, thermal cycler GeneAmp® 
PCR System 2700 (Applied Biosystems) was applied 
the following conditions program: pre-amplification 
at 94°C for 3 minutes; amplification – 30 cycles, each 
consisting of: 94°C – 30 s, 53°C – 60 s, 72°C – 60 s; final 
elongation 72°C for 5 minutes. The obtained amplifi-
cation products in the volume of 6 μl were mixed with 
Loading Buffer DNA IV (AppliChem) and separated 
in 1.5% agarose gel (Bio-Rad) in 1 × TBE (Bio-Rad), at 
9 V/cm for 1.5 hour in MINI SUB™ DNA CELL (Bio-
Rad) or SUB-CELL® GT (Bio-Rad). The 100–3000 bp 
DNA size marker (Solis BioDyne) was used. After 
staining for 30 minutes in ethidium bromide solution 
and subsequent washing for 20 minutes with deionized 
water, gels were visualized in UV light with Quantity 
One (Bio-Rad) system, photographed and stored. The 
gene identification was done on the basis of fragment 
size, as presented in Figure 1. Detection of a 504 bp 
product for the strain tested and the PAO1 control 
simultaneously was interpreted as a positive result.
Statistical analysis was performed using chi square 
test (χ2) with α ≤ 0.05 to determine the significance of 
the difference in exoS gene frequencies between MDS 
and MDR strains groups.
Fig. 1. An example of gel showing an electrophoretic separation
of the exoS gene amplification product
* M-DNA size standard ranging from 100 to 3000 bp; 1–9 numbers
of the examined strains; 10 – positive control; 11 – negative control;
the arrow indicates the expected product size (504 bp).
Results and Discussion
In the present work exoS gene was found in 72 
(48.7%) of the investigated P. aeruginosa strains. Posi-
tive results were obtained for 44 (53.0%) of MDS and 
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28 (43.1%) of MDR tested strains. An example is shown 
in Figure  1. The difference in exoS gene prevalence 
between both examined groups was not statistically 
significant (p = 0.1505).
Since couple of years, there have been some infor-
mation on reduced virulence of MDR P. aeruginosa 
strains available in the scientific literature (Deptuła 
and Gospodarek, 2010; di Martino et al., 2002; Ramisse 
et al., 2000, Khosravi et al., 2016). One of the explana-
tions of this phenomenon is that bacteria cells some-
how selectively silence some genes and activate other 
ones, currently more important from the survival point 
of view. However, in the available literature there are 
only a few reports on comparison of virulence factors 
genes expression in P. aeruginosa strains sensitive and 
resistant to several antimicrobials groups (Linares et al., 
2005; Fuse et al., 2012). Linares and co-workers (2005) 
observed reduction of the type-III secretion compounds 
in P. aeruginosa after overexpression of particular mul-
tidrug efflux pumps. Interestingly, on the basis of the 
Fuse et al. studies (2012), synthesis of another P. aerugi­
nosa important virulence factor and pigment-pyocyanin 
is also reduced in MDR strains. Moreover, its synthe-
sis also decreases after metallo-beta-lactamases genes 
transduction into non-MDR P. aeruginosa strains. These 
facts could explain in what manner the more resistant 
strains cause infections with the lowest frequency.
A second explanation for the reduced virulence 
of MDR strains is the appropriate bacterial genome 
management that allows for survival in the antibiotic-
supplemented environment. In the literature numerous 
researchers characterize P. aeruginosa genetic features 
in terms of different conditions, e.g. origin, clinical 
specimen, hospitalization time. However, still none 
information on virulence genes frequency in MDS and 
MDR groups of P. aeruginosa strains can be found in 
the relevant literature.
There is a wide diversity in the prevalence of P. aeru­
ginosa genetic features. In the available positions the 
highest percentage of P. aeruginosa strains carrying 
exoS gene was found in the studies conducted by Ting-
pej et al. (2007) and Idris et al. (2012), reaching 100% 
and 93.2%, respectively. In contrary, Azimi et al. (2016) 
had recently confirmed the exoS gene presence only 
in 26.3% of the examined strains which is the lowest 
value ever mentioned.
Lanotte et al. (2004) studies revealed exoS gene pres-
ence in a range of 64.7% up to 93.8% of the examined 
strains. The values were related to the clinical specimen 
type which P. aeruginosa strains were isolated from. 
Amongst the clinical strains the lowest percentage was 
observed for the strains isolated from urine. One of the 
highest values was found in sputum- and lung-derived 
isolates. It would suggest the crucial role of exoenzyme 
S presence in pulmonary infections. 
According to the results obtained by Khosravi et al. 
(2016), exoS gene was noted in almost 86% of the 
strains derived from patients’ burns while in the work of 
Wolska and Szweda (2009) the gene was observed in 
75.8% of the strains tested. ExoS gene in the study 
mentioned above was noted with the lowest frequency 
amongst all of the examined strains when compared to 
other virulence factors genes. The study of exoS gene 
prevalence including the highest number of P. aerugi­
nosa strains was carried out by Pirnay et al. (2009). They 
had investigated 328 unrelated P. aeruginosa strains iso-
lated during 125 years, in 69 places from 30 countries 
in 5 continents. The exoS gene was present in 72.6% of 
the strains. Those strains were isolated not only from 
hospitalized patients, but also from animals and envi-
ronmental samples. Results similar to those obtained by 
Pirnay et al. (2009), but exclusively for clinical P. aeru­ 
ginosa strains, using PCR and also Southern hybridi-
zation for the first one, were found by Feltman et al. 
(2001) and Garey et al. (2008). The gene was present in 
72% and 70.5% of the examined strains, respectively. 
According to Fazeli and Momtaz (2014) the exoS gene is 
one of the most common (67.64%) virulence gene found 
amongst the tested strains. Similar level of the exoS 
gene presence (65.4%) among the examined P. aeru ­ 
ginosa strains was also noted by Yousefi-Avarvand 
et al. (2015). Another study done by Zhuo et al. (2010) 
detected exoS gene in 65.1% of the examined P. aerugi­
nosa strains collected from patients from five hospitals. 
Almost 64% of P. aeruginosa isolates from ocular infec-
tions, examined by Choy et al. (2008) were also positive 
for exoS gene. Mitov and co-workers (2010) showed the 
presence of exoS gene amongst 62.4% of the examined 
P. aeruginosa strains but they did not confirm differ-
ences in the spread of the gene neither amongst MDR, 
nor non-MDR strains population. In the work pub-
lished by Amirmozafari et al. (2016) the frequency of 
exoS gene reached 61% but none association was found 
between strains resistance and gene presence. The 
results demonstrated by Finlayson and Brown (2011) 
show that exoS genes presence is observed in approxi-
mately half of the examined strains while Winstanley 
et al. (2005) has confirmed exoS gene presence only in 
38% of P. aeru ginosa strains that had been examined. 
These latter values seems to be really close to the results 
obtained in this study where exoS gene was present in 
43.1% up to 53.0% of the examined non-duplicated 
MDR and MDS strains, respectively.
Noteworthy, in the available literature, there is spare 
information on reduced exoS genes carriage amongst 
MDR P. aeruginosa strains to compare to our results. 
The only paper that includes similar research approach 
(Khosravi et al., 2016) shows limited exoS gene presence 
in MDR comparing to overall strains population (77.1% 
vs. 85.8%) derived from burn patients.
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Although, the aim of this study was only to estimate 
the exoS gene carriage, not the ability of exoenzyme S 
synthesis, it is also very interesting issue. Zhang and 
Wei (2009) study proved that the expression of viru-
lence factors in P. aeruginosa strains is a very com-
plex process. Exoenzyme S synthesis level may be 
for example raised by the glutathione concentration. 
Noteworthy, exoenzyme S is not always expressed, 
Tartor and El-Naenaeey (2016) detected its synthesis 
amongst 78.6% of P. aeruginosa strains. Similarly, results 
obtained by Tingpej et al. (2007) revealed that only 77% 
of the exoS gene-carrying strains synthesized this toxin 
in the respiratory tract infections studies. Meanwhile, 
during infection exoenzyme S production is necessary 
to invade e.g. epithelial cells, what is achieved by its 
injection directly into human cells (Heimer et al., 2013; 
Hayashi et al., 2015). 
Joly et al. (2005), using RT-PCR, indicated increased 
exoS expression at the beginning of experimental 
P. aeru ginosa pneumonia in rat model. The highest 
exo enzyme S transcript levels were present during the 
first two days of the infection. Its presence was linked 
with 29% mortality and, after two days, a drop in its 
synthesis was observed. Similar correlation in the ani-
mal model of exoS expression was indicated by Pierre 
et al. (2008). These authors claim that the expression 
of all genes connected with type-III secretion system 
decreases during chronic disease. In contrary to this 
conclusion, Hamood et al. (1996) and Rumbaugh et al. 
(1999a) claim that prolonged P. aeruginosa infection 
seems to increase exoenzyme S production. Moreover, 
it is synthesized significantly more often by wound- and 
urinary tract infections-derived P. aeruginosa strains 
(Hamood et al., 1996). 
Taken together, the results of this study indicate 
for the first time, although not statistically important, 
reduced exoenzyme S genes carriage in MDR P. aeru­
ginosa strains when compared to MDS. All the facts 
mentioned above prove the advanced nature of exoS 
gene carriage, as well as expression, and indicate that 
further studies on that issue are necessary.
Conclusions
Exoenzyme S gene is not present in all P. aeruginosa 
strains, therefore not all of the strains have the ability 
to synthesize this virulence factor.
ExoS gene is noted more often amongst multi drug-
sensitive P. aeruginosa strains, when compared to mul-
tidrug-resistant ones, but no statistically significant 
difference was observed. 
The reduced virulence of multidrug-resistant P. aeru­
ginosa strains is more likely caused by gene expression 
regulation, and not by the absence of virulence genes.
Acknowledgements
This research was financially supported by the Nicolaus Coper-
nicus University funds for the maintenance of the research potential 
of the Department of Microbiology.
Literature
Amirmozafari N., J. Fallah Mehrabadi and A. Habibi. 2016. Asso-
cia tion of the exotoxin A and exoenzyme S with antimicrobial resis-
tance in Pseudomonas aeruginosa strains. Arch. Iran Med. 19(5): 
353–358.
Azimi S., H.S. Kafil, H.B. Baghi, S. Shokrian, K. Najaf, M. Asghar-
zadeh, M. Yousefi, F. Shahrivar and M. Aghazadeh. 2016. Presence 
of exoY, exoS, exoU and exoT genes, antibiotic resistance and biofilm 
production among Pseudomonas aeruginosa isolates in Northwest 
Iran. GMS Hyg. Infect. Control. 11: Doc04.
Barbieri J.T. 2000. Pseudomonas aeruginosa exoenzyme S, a bifunc-
tional type-III secreted cytotoxin. Int. J. Med. Microbiol. 290: 381–387.
Barbieri J.T. and J. Sun. 2004. Pseudomonas aeruginosa ExoS and 
ExoT. Rev. Physiol. Biochem. Pharmacol. 152: 79–92.
Bruno T.F., D.E. Woods and C.H. Mody. 2000. Exoenzyme  S 
from Pseudomonas aeruginosa induces apoptosis in T lymphocytes. 
J. Leukoc. Biol. 67: 808–816.
Choy M.H., F. Stapleton, M.D. Willcox and H. Zhu. 2008. Com-
parison of virulence factors in Pseudomonas aeruginosa strains 
isolated from contact lens- and non-contact lens-related keratitis. 
J. Med. Microbiol. 57(12): 1539–1546.
Deptuła A. and E. Gospodarek. 2010. Reduced expression of viru-
lence factors in multidrug-resistant Pseudomonas aeruginosa strains. 
Arch. Microbiol. 192: 79–84.
Di Martino P., H. Gagnière, H. Berry and R. Bret. 2002. Anti-
biotic resistance and virulence properties of Pseudomonas aerugi­
nosa strains from mechanically ventilated patients with pneumonia 
in intensive care units: comparison with imipenem-resistant extra-
respiratory tract isolates from uninfected patients. Microbes Infect. 
4: 613–620.
Falagas M.E., P.K. Koletsi and I. Bliziotis. 2006. The diversity of 
definitions of multidrug-resistant (MDR) and pandrug-resistant 
(PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. 
Review. J. Med. Microbiol. 55(12): 1619–1629.
Fazeli N. and H. Momtaz. 2014. Virulence gene profiles of multi-
drug-resistant Pseudomonas aeruginosa isolated from Iranian hos-
pital infections. Iran Red. Crescent Med. J. 16(10): e15722.
Feltman H., G. Schulert, S. Khan, M. Jain, L. Peterson and 
A.R. Hauser. 2001. Prevalence of type III secretion genes in clinical 
and environmental isolates of Pseudomonas aeruginosa. Microbiol. 
147: 2659–2669.
Finlayson E.A. and P.D. Brown. 2011. Comparison of antibiotic 
resistance and virulence factors in pigmented and non-pigmented 
Pseudomonas aeruginosa. West Indian Med. J. 60(1): 24–32.
Frithz-Lindsten E., Y. Du, R. Rosqvist and A. Forsberg. 1997. 
Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa 
via type III-dependent translocation induces phagocytosis resis-
tance, cytotoxicity and disruption of actin microfilaments. Mol. 
Microbiol. 25: 1125–1139.
Fuse K., S. Fujimura, T. Kikuchi, K. Gomi, Y. Iida, T. Nukiwa 
and A. Watanabe. 2013. Reduction of virulence factor pyocyanin 
production in multidrug-resistant Pseudomonas aeruginosa. J. Infect. 
Chemother. 19(1): 82–88. 
Garey K.W., Q.P. Vo, M.T. Larocco, L.O. Gentry and V.H. Tam. 
2008. Prevalence of type III secretion protein exoenzymes and 
antimicrobial susceptibility patterns from bloodstream isolates of 
patients with Pseudomonas aeruginosa bacteremia. J. Chemother. 
20(6): 714–720.
ExoS gene in MDS and MDR P. aeruginosa strains4 431
Hamood A.N., J.A. Griswold and C.M. Duhan. 1996. Production 
of extracellular virulence factors by Pseudomonas aeruginosa isolates 
obtained from tracheal, urinary tract, and wound infections. J. Surg. 
Res. 61(2): 425–432.
Hayashi N., H. Nishizawa, S. Kitao, S. Deguchi, T. Nakamura, 
A. Fujimoto, M. Shikata and N. Gotoh. 2015. Pseudomonas aeru­
ginosa injects type III effector ExoS into epithelial cells through the 
function of type IV pili. FEBS Lett. 589(8): 890–896. 
Heimer S.R., D.J. Evans, M.E. Stern, J.T. Barbieri, T. Yahr and 
S.M. Fleiszig. 2013. Pseudomonas aeruginosa utilizes the type III 
secreted toxin ExoS to avoid acidified compartments within epi-
thelial cells. PLoS One 8(9): e73111. 
Hill D., B. Rose, A. Pajkos, M. Robinson, P. Bye, S. Bell, M. Elkins, 
B. Thompson, C. Macleod, S.D. Aaron and others. 2005. Anti biotic 
susceptibilities of Pseudomonas aeruginosa isolates derived from 
patients with cystic fibrosis under aerobic, anaerobic and biofilm 
conditions. J. Clin. Microbiol. 43: 5085–5090.
Hsu D.I., M.P. Okamoto, R. Murthy and A. Wong-Beringer. 2005. 
Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for 
acquisition and impact on outcomes. J. Antimicrob. Chemother. 55: 
535–541.
Idris S.N., M.N. Desa, M.N. Aziz and N.M. Taib. 2012. Anti-
microbial susceptibility pattern and distribution of exoU and exoS 
in clinical isolates of Pseudomonas aeruginosa at a Malaysian hos-
pital. Southeast Asian J. Trop. Med. Public Health 43(1): 116–123.
Joly B., M. Pierre, S. Auvin, F. Colin, F. Gottrand, B. Guery and 
M.O. Husson. 2005. Relative expression of Pseudomonas aeruginosa 
virulence genes analyzed by a real time RT-PCR method during lung 
infection in rats. FEMS Microbiol. Lett. 243: 271–278.
Khosravi A.D., F. Shafie, E. Abbasi Montazeri and S. Rostami. 
2016. The frequency of genes encoding exotoxin A and exoenzyme S 
in Pseudomonas aeruginosa strains isolated from burn patients. 
Burns 42(5): 1116–1120.
Krueger K.M. and J.T. Barbieri. 1995. The family of bacterial ADP-
ribosylating exotoxins. Clin. Microbiol. Rev. 8: 34–37.
Lanotte P., S. Watt, L. Mereghetti, N. Dartiguelongue, A. Rastegar-
Lari, A. Goudeau and R. Quentin. 2004. Genetic features of Pseu­
domonas aeruginosa isolates from cystic fibrosis patients compared 
with those of isolates from other origins. J. Med. Microbiol. 53: 73–81.
Linares J.F., J.A. López, E. Camafeita, J.P. Albar, F. Rojo and 
J.L. Martínez. 2005. Overexpression of the multidrug efflux pumps 
MexCD-OprJ and MexEF-OprN is associated with a reduction of 
type III secretion in Pseudomonas aeruginosa. J. Bacteriol. 187(4): 
1384–1391.
Magiorakos A.P., A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Fala-
gas, C.G. Giske, S. Harbarth, J.F. Hindler, G. Kahlmeter, B. Olsson- 
-Liljequist and others. 2012. Multidrug-resistant, extensively drug-
resistant and pandrug-resistant bacteria: an international expert 
proposal for interim standard definitions for acquired resistance. 
Clin. Microbiol. Infect. 18(3): 268–281.
Mitov I., T. Strateva and B. Markova. 2010. Prevalence of virulence 
genes among Bulgarian nosocomial and cystic fibrosis isolates of 
Pseudomonas aeruginosa. Braz. J. Microbiol. 41(3): 588–595.
Obritsch M.D., D.N. Fish, R. MacLaren and R. Jung. 2004. Natio-
nal surveillance of antimicrobial resistance in Pseudomonas aerugi­
nosa isolates obtained from intensive care unit patients from 1993 
to 2002. Antimicrob. Agents Chemother. 48: 4606–4610.
Pierre M., R. Le Berre, H. Tiesset, K. Faure, B. Guery, J.L. Desseyn, 
C. Galabert, L. Béghin, C. Beermann, F. Gottrand and others. 
2008. Kinetics of Pseudomonas aeruginosa virulence gene expres-
sion during chronic lung infection in the murine model. Med. Mal. 
Infect. 38: 318–323.
Pirnay J.P., F. Bilocq, B. Pot, P. Cornelis, M. Zizi, J. Van Eldere, 
P. Deschaght, M. Vaneechoutte, S. Jennes, T. Pitt and others. 2009. 
Pseudomonas aeruginosa population structure revisited. PLoS One 
4: 1–20.
Ramisse F., C. van Delden, S. Gidenne, J. Cavallo and E. Hernan-
dez. 2000. Decreased virulence of a strain of Pseudomonas aeru­
ginosa O12 overexpressing a chromosomal type 1 beta-lactamase 
could be due to reduced expression of cell-to-cell signaling depen-
dent virulence factors. FEMS Immunol. Med. Microbiol. 28: 241–245.
Rumbaugh K.P., J.A. Griswold and A.N. Hamood. 1999a. Pseudo­
monas aeruginosa strains obtained from patients with tracheal, 
urinary tract and wound infection: variations in virulence factors 
and virulence genes. J. Hosp. Infect. 43(3): 211–218.
Rumbaugh K.P., A.N. Hamood and J.A. Griswold. 1999b. Analysis 
of Pseudomonas aeruginosa clinical isolates for possible variations 
within the virulence genes exotoxin A and exoenzyme S. J. Surg. Res. 
82(1): 95–105.
Stover C.K., X.Q. Pham, A.L. Erwin, S.D. Mizoguchi, P. Warrener, 
M.J. Hickey, F.S. Brinkman, W.O. Hufnagle, D.J. Kowalik, 
M. Lagrou and others. 2000. Complete genome sequence of Pseudo­ 
monas aeruginosa PAO1, an opportunistic pathogen. Nature 406: 
959–964.
Tam V., A.N. Schilling, G. Vo, S. Kabbara, A.L. Kwa, N.P. Wieder-
hold and R.E. Lewis. 2005. Pharmacodynamics of polymyxin  B 
against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49: 
3624–3630.
Tartor Y.H. and E.Y. El-Naenaeey. 2016. RT-PCR detection of exo-
toxin genes expression in multidrug resistant Pseudomonas aerugi­
nosa. Cell. Mol. Biol. (Noisy-le-grand). 62(1):56–62.
Tingpej P., L. Smith, B. Rose, H. Zhu, T. Conibear, K. Al Nassafi, 
J. Manos, M. Elkins, P. Bye, M. Willcox and others. 2007. Pheno-
typic characterization of clonal and nonclonal Pseudomonas aerugi­
nosa strains isolated from lungs of adults with cystic fibrosis. J. Clin. 
Microbiol. 45(6): 1697–1704.
Winstanley C., S.B. Kaye, T.J. Neal, H.J. Chilton, S. Miksch, 
C.A. Hart and Microbiology Ophthalmic Group. 2005. Genotypic 
and phenotypic characteristics of Pseudomonas aeruginosa isolates 
associated with ulcerative keratitis. J. Med. Microbiol. 54: 519–526.
Wolska K. and P. Szweda. 2009. Genetic features of clinical Pseudo­
monas aeruginosa strains. Pol. J. Microbiol. 58(3): 255–260.
Yousefi-Avarvand A., R. Khashei, H. Sedigh Ebrahim-Saraie, 
A. Emami, K. Zomorodian and M. Motamedifar. 2015. The fre-
quency of exotoxin A and exoenzymes S and U genes among clinical 
isolates of Pseudomonas aeruginosa in Shiraz, Iran. Int. J. Mol. Cell 
Med. 4(3):167–173.
Zhang Y. and Y. Wei. 2009. Impact of glutathione on the gene 
expression of exoY and exoS in Pseudomonas aeruginosa. Wei Sheng 
Wu Xue Bao 49: 603–608.
Zhuo C., L.X. Wang, S.N. Xiao, H.Y. Li, G.X. Qiu and N.S. Zhong. 
2010. Clinical significance of virulence-related genes of type  III 
secretion system of Pseudomonas aeruginosa. Zhonghua Shao Shang 
Za Zhi 26(5): 354–359.

